Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Telephone Interview of Patients That Participated in the the Pivotal Betaferon MS Trial.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01031459
Recruitment Status : Completed
First Posted : December 14, 2009
Last Update Posted : January 5, 2012
Information provided by:

Brief Summary:

The purpose of this study is to investigate the clinical status of patients who participated in the original pivotal Betaseron study at 20 years after randomized treatment initiationStudy end-points include:

  1. Mortality - All-cause mortality - Cause specific mortality - Multiple sclerosis-related mortality
  2. EDSS (Expanded Disability Status Scale)
  3. Cognition
  4. Resource use
  5. SPMS (Secondary Progressive Multiple Sclerosis) status
  6. Employment history

Condition or disease Intervention/treatment
Multiple Sclerosis Drug: Betaseron (Interferon beta-1b, BAY86-5046)

Layout table for study information
Study Type : Observational
Actual Enrollment : 176 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: An Observational 20-year, Cross-sectional, Long-term Follow up of the Patient Cohort Enrolled in the Pivotal Study of Betaseron® (Interferon Beta-1b) in Relapsing-remitting Multiple Sclerosis
Study Start Date : January 2010
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Group/Cohort Intervention/treatment
Group 1 Drug: Betaseron (Interferon beta-1b, BAY86-5046)
Telephone survey of all patients.

Primary Outcome Measures :
  1. Descriptive exploration of mortality, EDSS, cognition, resource use, SPMS status and employment history by length of exposure to Betaseron and stratified by the original clinical trial group assignment (1.6 MIU, 8 MIU, placebo) [ Time Frame: 20 years ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with MS that participated in the 16Y-LTF and Pivitol studies

Inclusion Criteria:

  • Previously enrolled in the Betaseron pivotal study protocols TB01-35686 in the US and TB01-35886 in Canada (total, N=372)
  • Patient, caregiver, or legal guardian must provide written informed consent
  • Patient must confirm her/his ability and agreement to participate in the study at the beginning of the phone call

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01031459

Layout table for location information
United States, Alabama
Birmingham, Alabama, United States, 35249
United States, Arizona
Tucson, Arizona, United States, 85741-3537
United States, California
San Francisco, California, United States, 94117
United States, Illinois
Chicago, Illinois, United States, 60637-1470
United States, Maryland
Baltimore, Maryland, United States, 21201
United States, Pennsylvania
Philadelphia, Pennsylvania, United States, 19107
Canada, British Columbia
Vancouver, British Columbia, Canada, V6T 2B5
Canada, Ontario
London, Ontario, Canada, N6A 5A5
Canada, Quebec
Montreal, Quebec, Canada, H2L 4M1
Montreal, Quebec, Canada, H3A 2B4
Sponsors and Collaborators
Layout table for investigator information
Study Director: Bayer Study Director Bayer
Layout table for additonal information
Responsible Party: Global Medical Affairs Therapeutic Area Head, Bayer Healthcare Phamaceuticals Inc. Identifier: NCT01031459    
Other Study ID Numbers: 14261
20Y-LTF ( Other Identifier: company internal )
First Posted: December 14, 2009    Key Record Dates
Last Update Posted: January 5, 2012
Last Verified: January 2012
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Interferon beta-1b
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs
Adjuvants, Immunologic